Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength (Ascending) SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00378-0344-01 00378-0344 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 In Use
00378-0344-05 00378-0344 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 In Use
00378-0344-53 00378-0344 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 Aug. 7, 2011 In Use
00378-0344-93 00378-0344 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 In Use
45963-0539-30 45963-0539 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 27, 2007 In Use
70934-0809-83 70934-0809 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 22, 2021 Feb. 28, 2025 In Use
70934-0809-87 70934-0809 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 22, 2021 Feb. 28, 2025 In Use
70934-0809-88 70934-0809 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 16, 2021 Nov. 30, 2024 In Use
70934-0809-95 70934-0809 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 8, 2020 Feb. 28, 2025 In Use
80425-0075-01 80425-0075 Ondansetron HCL Ondansetron HCL 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 31, 2007 In Use
80425-0075-02 80425-0075 Ondansetron HCL Ondansetron HCL 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 31, 2007 In Use
80425-0075-03 80425-0075 Ondansetron HCL Ondansetron HCL 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 31, 2007 In Use
80425-0075-04 80425-0075 Ondansetron HCL Ondansetron HCL 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 31, 2007 In Use
80425-0075-05 80425-0075 Ondansetron HCL Ondansetron HCL 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 31, 2007 In Use
51655-0196-53 51655-0196 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 20, 2022 In Use
51655-0196-80 51655-0196 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 20, 2022 In Use
51655-0196-87 51655-0196 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral March 13, 2023 In Use
51655-0196-04 51655-0196 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 27, 2023 In Use
68788-9402-01 68788-9402 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 12, 2012 In Use
68788-9402-03 68788-9402 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 12, 2012 In Use
68788-9402-05 68788-9402 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 23, 2017 In Use
68788-9402-06 68788-9402 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 23, 2017 In Use
68788-9402-02 68788-9402 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 23, 2017 In Use
60687-0647-01 60687-0647 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 20, 2022 Aug. 31, 2024 In Use
68001-0558-55 68001-0558 Methylprednisolone Methylprednisolone 8.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Jan. 31, 2023 In Use
68084-0221-01 68084-0221 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 1, 2023 In Use
68084-0221-11 68084-0221 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 3, 2012 In Use
70934-0264-10 70934-0264 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral March 9, 2020 Jan. 31, 2025 In Use
70934-0264-12 70934-0264 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 7, 2019 Jan. 31, 2025 In Use
70518-1551-00 70518-1551 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 23, 2018 In Use
70518-1551-01 70518-1551 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 1, 2019 Feb. 18, 2020 In Use
70518-1551-02 70518-1551 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Nov. 21, 2023 In Use
00469-0725-60 00469-0725 enzalutamide Xtandi 80.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Aug. 4, 2020 In Use
00310-1350-30 00310-1350 Osimertinib Tagrisso 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 13, 2015 In Use
00310-1350-95 00310-1350 Osimertinib Tagrisso 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral March 15, 2019 In Use
00002-2980-26 00002-2980 Selpercatinib RETEVMO 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral May 8, 2020 In Use
00002-2980-60 00002-2980 Selpercatinib RETEVMO 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral May 8, 2020 In Use
00003-0855-22 00003-0855 Dasatinib Sprycel 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Oct. 28, 2010 In Use
00781-2322-46 00781-2322 Aprepitant Aprepitant 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Dec. 27, 2016 In Use
00781-2322-68 00781-2322 Aprepitant Aprepitant 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Dec. 27, 2016 In Use
00006-0461-01 00006-0461 Aprepitant Emend 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral March 26, 2003 In Use
00006-0461-02 00006-0461 Aprepitant Emend 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral March 26, 2003 In Use
00006-0461-06 00006-0461 Aprepitant Emend 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral March 26, 2003 April 30, 2020 In Use
00006-0461-12 00006-0461 Aprepitant Emend 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral March 26, 2003 In Use
00006-0461-30 00006-0461 Aprepitant Emend 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral March 26, 2003 July 14, 2010 In Use
72579-0011-01 72579-0011 Zanubrutinib BRUKINSA 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Nov. 14, 2019 Sept. 30, 2021 In Use
72579-0011-02 72579-0011 Zanubrutinib BRUKINSA 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Nov. 14, 2019 In Use
13668-0592-84 13668-0592 APREPITANT APREPITANT 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Oct. 21, 2020 In Use
13668-0592-86 13668-0592 APREPITANT APREPITANT 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Oct. 21, 2020 In Use
54868-5231-01 54868-5231 Aprepitant Emend 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral June 29, 2005 In Use

Found 10,000 results in 15 milliseconds — Export these results